iProtics
PrivateLast Round
Seed
Oct 10, 2024
Total Funding Raised
$850,000
Company Overview
iProtics operates in Healthcare & Life Sciences and is based in Leiden. Its latest recorded funding round was a Seed round in October 2024.
iProtics is a biotechnology company developing selective immunoproteasome inhibitors to treat hematological cancers and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iProtics Comparables
Compare iProtics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IpiNovyx Bio | 87% | |
| QLi5 Therapeutics GmbH | 82% | |
| Aurinia Pharmaceuticals Inc. | 76% |
For institutional investors. Book with your work email.
iProtics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 10, 2024 | ||||
| Grant | Mar 20, 2024 | ||||
| Accelerator | Sep 9, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iProtics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Libertatis Ergo Holding | Seed |
| Netherlands Organization for Scientific Research | Grant |
| Life Sciences @ Work Venture Challenge | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 10, 2024
$380K round led by uniiq
- Mar 20, 2024
$220K grant from Netherlands Organization for Scientific Research.
For institutional investors. Book with your work email.
iProtics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iProtics's valuation, stock price, and market status.
Is iProtics a public or private company?
iProtics is a private company.
What is the current stock price of iProtics?
iProtics is a private company, so its shares have no public market price. Caplight tracks iProtics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iProtics worth (valuation)?
Valuation information for iProtics is not publicly available.
Can I buy iProtics stock?
iProtics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iProtics's last funding round?
iProtics's most recent funding round was Seed on October 10, 2024.
Who are the main investors in iProtics?
Key investors in iProtics include Libertatis Ergo Holding, Netherlands Organization for Scientific Research, Life Sciences @ Work Venture Challenge.
Will iProtics IPO soon?
No public IPO plans have been announced for iProtics.
How can I track iProtics secondary market activity?
Caplight tracks bids, offers, and trades in iProtics's shares on secondary markets.